Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

Adam Brufsky(University of Pittsburgh), Linda D. Bosserman(Wilshire Health and Community Services), R. Caradonna(Cancer Institute of Florida), Barbara Haley(Southwestern Medical Center), C. Michael Jones(Jones Institute), Halle C. F. Moore(Cleveland Clinic), Lixian Jin(Novartis (United States)), Ghulam Warsi(Novartis (United States)), Solveig G. Ericson(Novartis (United States)), Edith A. Perez(Jacksonville College)
Clinical Breast Cancer
May 1, 2009
10.3816/cbc.2009.n.015
Cited by 214

Abstract

Related Papers

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Anthony Howell, Jack Cuzick, M Baum et al.|The Lancet|2005|2.3k
Diagnosis of osteoporosis and assessment of fracture risk
John А. Kanis|The Lancet|2002|2.2k
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Paul E. Goss, James N. Ingle, Silvana Martino et al.|New England Journal of Medicine|2003|1.8k
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
The Breast International Group (BIG) 1-98 Collaborative Group|New England Journal of Medicine|2005|1.6k
Osteoporosis
Philip N. Sambrook, Cyrus Cooper|The Lancet|2006|1.2k